Watson welcomes Bodine to board of directors
MORRISTOWN, N.J. Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced the addition of Christopher Bodine to its board of directors, effective immediately.
Bodine brings with him 36 years of experience in the chain drug industry with two of the nation’s leading retail and healthcare companies.
“Chris is a terrific addition to our board of directors, and we are extremely pleased to bring his unique customer insights and perspective to Watson,” said Paul Bisaro, Watson president and CEO. “We look forward to his counsel as Watson embarks on its new global challenges, as well as the guidance and support that he can bring to our distribution business.”
Bodine retired from CVS Caremark in 2009 after 24 years with the company. For years, he has been active in the industry as a member of several boards and committees. In 2005, he was recognized by Mass Market Retailers magazine as the publication’s Top Retail Merchandiser and was named one of Drug Store News’ “Five People Who Made a Difference” in retail.
PCMA launches ad campaign to push Senate on biosimilars
WASHINGTON An organization of the country’s pharmacy benefit managers has launched a new ad campaign to nudge senators on biosimilars.
The Pharmaceutical Care Management Association announced Thursday the launch of the campaign, directed at members of the U.S. Senate Health, Education, Labor and Pensions committee, hoping they will include “real” biosimilars legislation as part of healthcare reform.
The ad features a photo of a toddler and the caption “Meet the first recipient of an affordable biologic for hemophilia. He’ll be 66 years old when he finally gets it.”
“If this week’s report is accurate that Washington and the drug company lobby have reached some kind of new health reform ‘agreement,’ we sincerely hope that biogenerics is not part of it,” PCMA president and CEO Mark Merritt said in a statement. “The drug lobby will truly have reason to celebrate if Washington either ignores biogenerics reform or, worse, establishes a new process that could actually forbid competition for years after patents expire.”
Medical care for pre-diabetes costs nation $25 billion annually, new data shows
WASHINGTON One-in-4 American adults suffers from a silent condition known as pre-diabetes, a condition that costs the nation $25 billion a year in medical costs, according to new data.
Studies also show healthcare costs attributed with some 180,000 pregnant women diagnosed with gestational diabetes are estimated at $623 million a year.
In response to high diabetic healthcare costs, The American Diabetes Association recently engaged The Lewin Group to build upon a 2008 study that determined the estimated total direct and indirect costs of diagnosed diabetes in the United States to be $174 billion.
“It is absolutely critical that we understand the economic impact of diabetes on the nation so that we can develop health care policies that can effectively support the necessary behavior change and aggressive medical management needed to stem the diabetes epidemic,” said Dana Haza, senior director of NCDP, an initiative created by Novo Nordisk to drive systems change at the national and local level.
The studies, conducted by The Lewin Group, can be found in the current edition of the peer-reviewed journal Population Health Management.